Inhibitory B7 family members in human ovarian carcinoma

Advances in Experimental Medicine and Biology

Volumn 622, Issue , 2008, Pages 261-271

  Wei, Shuang ^a   Curiel, Tyler ^a   Coukos, George ^a   Liu, Rebecca ^a   Zou, Weiping ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; B7 H1 ANTIGEN; B7 H4 ANTIGEN; MESSENGER RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CARCINOMA; EFFECTOR CELL; EX VIVO STUDY; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; NONHUMAN; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

ANTIGENS, CD80; CARCINOMA; FEMALE; HUMANS; IMMUNOLOGY; METABOLISM; OVARIAN NEOPLASMS;

EID: 84934440448     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-68969-2_21     Document Type: Review

References (71)

1. Kaufman, H.L., and M.L. Disis. 2004. Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest 113:664-667.
2. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274.
3. Pardoll, D. 2003. Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807-839.
4. Khong, H.T., and N.P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999-1005.
5. Cerundolo, V., I.F. Hermans, and M. Salio. 2004. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5:7-10.
6. Gilboa, E. 2004. The promise of cancer vaccines. Nat Rev Cancer 4:401-411.
7. Munn, D.H., and A.L. Mellor. 2004. IDO and tolerance to tumors. Trends Mol Med 10:15-18.
8. Finn, O.J. 2003. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630-641.
9. Yu, P., Y. Lee, W. Liu, R.K. Chin, J. Wang, Y. Wang, A. Schietinger, M. Philip, H. Schreiber, and Y.X. Fu. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5:141-149.
10. Schreiber, H., T.H. Wu, J. Nachman, and W.M. Kast. 2002. Immunodominance and tumor escape. Semin Cancer Biol 12:25-31.
11. Lotze, M.T., and M. Papamichail. 2004. A primer on cancer immunology and immunotherapy. Cancer Immunol Immunother 53:135-138.
12. Lotze, M.T., B. Hellerstedt, L. Stolinski, T. Tueting, C. Wilson, D. Kinzler, H. Vu, J.T. Rubin, W. Storkus, H. Tahara, E. Elder, and T. Whiteside. 1997. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Sci Am 3(Suppl 1):S109-S114.
13. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.
14. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y.J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811.
15. Mullins, D.W., S.L. Sheasley, R.M. Ream, T.N. Bullock, Y.X. Fu, and V.H. Engelhard. 2003. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 198:1023-1034.
16. Plautz, G.E., P.A. Cohen, and S. Shu. 2003. Considerations on clinical use of T cell immunotherapy for cancer. Arch Immunol Ther Exp (Warsz) 51:245-257.
17. Flanagan, K., and H.L. Kaufman. 2006. Chemokines in tumor immunotherapy. Front Biosci 11:1024-1030.
18. Slingluff, C.L., Jr., G.R. Petroni, G.V. Yamshchikov, D.L. Barnd, S. Eastham, H. Galavotti, J.W. Patterson, D.H. Deacon, S. Hibbitts, D. Teates, P.Y. Neese, W.W. Grosh, K.A. Chianese- Bullock, E.M. Woodson, C.J. Wiernasz, P. Merrill, J. Gibson, M. Ross, and V.H. Engelhard. 2003. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016-4026.
19. Weber, J.S., and A. Aparicio. 2001. Novel immunologic approaches to the management of malignant melanoma. Curr Opin Oncol 13:124-128.
20. Disis, M.L., and S. Rivkin. 2003. Future directions in the management of ovarian cancer. Hematol Oncol Clin North Am 17:1075-1085.
21. Knutson, K.L., T.J. Curiel, L. Salazar, and M.L. Disis. 2003. Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematol Oncol Clin North Am 17:1051-1073.
22. Sica, G.L., I.H. Choi, G. Zhu, K. Tamada, S.D. Wang, H. Tamura, A.I. Chapoval, D.B. Flies, J. Bajorath, and L. Chen. 2003. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18:849-861.
23. Zang, X., P. Loke, J. Kim, K. Murphy, R. Waitz, and J.P. Allison. 2003. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100:10388-10392.
24. Prasad, D.V., S. Richards, X.M. Mai, and C. Dong. 2003. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18:863-873.
25. Choi, I.H., G. Zhu, G.L. Sica, S.E. Strome, J.C. Cheville, J.S. Lau, Y. Zhu, D.B. Flies, K. Tamada, and L. Chen. 2003. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 171:4650-4654.
26. Kryczek, I., L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, A. Lackner, X. Alvarez, A. Ochoa, L. Chen, and W. Zou. 2006. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203:871-881.
27. Bignotti, E., R.A. Tassi, S. Calza, A. Ravaggi, C. Romani, E. Rossi, M. Falchetti, F.E. Odicino, S. Pecorelli, and A.D. Santin. 2006. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol 103:405-416.
28. Tringler, B., W. Liu, L. Corral, K.C. Torkko, T. Enomoto, S. Davidson, M.S. Lucia, D.E. Heinz, J. Papkoff, and K.R. Shroyer. 2006. B7-H4 overexpression in ovarian tumors. Gynecol Oncol 100:44-52.
29. Simon, I., S. Zhuo, L. Corral, E.P. Diamandis, M.J. Sarno, R.L. Wolfert, and N.W. Kim. 2006. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 66:1570-1575.
30. Salceda, S., T. Tang, M. Kmet, A. Munteanu, M. Ghosh, R. Macina, W. Liu, G. Pilkington, and J. Papkoff. 2005. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 306:128-141.
31. Sun, Y., Y. Wang, J. Zhao, M. Gu, R. Giscombe, A.K. Lefvert, and X. Wang. 2006. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53:143-151.
32. Tringler, B., S. Zhuo, G. Pilkington, K.C. Torkko, M. Singh, M.S. Lucia, D.E. Heinz, J. Papkoff, and K.R. Shroyer. 2005. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11:1842-1848.
33. Krambeck, A.E., R.H. Thompson, H. Dong, C.M. Lohse, E.S. Park, S.M. Kuntz, B.C. Leibovich, M.L. Blute, J.C. Cheville, and E.D. Kwon. 2006. B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. Proc Natl Acad Sci USA 103:10391-10396.
34. Chen, L. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336-347.
35. Wyckoff, J., W. Wang, E.Y. Lin, Y. Wang, F. Pixley, E.R. Stanley, T. Graf, J.W. Pollard, J. Segall, and J. Condeelis. 2004. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022-7029.
36. Pollard, J.W. 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71-78.
37. Vakkila, J., and M.T. Lotze. 2004. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4:641-648.
38. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549-555.
39. Curiel, T.J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K.L. Knutson, B. Daniel, M.C. Zimmermann, O. David, M. Burow, A. Gordon, N. Dhurandhar, L. Myers, R. Berggren, A. Hemminki, R.D. Alvarez, D. Emilie, D.T. Curiel, L. Chen, and W. Zou. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 21:21.
40. Zou, W., V. Machelon, A. Coulomb-L'Hermin, J. Borvak, F. Nome, T. Isaeva, S. Wei, R. Krzysiek, I. Durand-Gasselin, A. Gordon, T. Pustilnik, D.T. Curiel, P. Galanaud, F. Capron, D. Emilie, and T.J. Curiel. 2001. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7:1339-1346.
41. Gabrilovich, D. 2004. Mechanisms and functional significance of tumour-induced dendriticcell defects. Nat Rev Immunol 4:941-952.
42. O'Neill, D.W., S. Adams, and N. Bhardwaj. 2004. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104:2235-2246.
43. Bingle, L., N.J. Brown, and C.E. Lewis. 2002. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254-265.
44. Zavadova, E., A. Loercher, S. Verstovsek, C.F. Verschraegen, M. Micksche, and R.S. Freedman. 1999. The role of macrophages in antitumor defense of patients with ovarian cancer. Hematol Oncol Clin North Am 13:135-144, ix.
45. Ohno, S., N. Suzuki, Y. Ohno, H. Inagawa, G. Soma, and M. Inoue. 2003. Tumor-associated macrophages: foe or accomplice of tumors? Anticancer Res 23:4395-4409.
46. Curiel, T.J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J.R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M.L. Disis, K.L. Knutson, L. Chen, and W. Zou. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949.
47. Kryczek, I., S. Wei, L. Zou, G. Zhu, P. Mottram, H. Xu, L. Chen, and W. Zou. 2006. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 177:40-44.
48. van Elsas, A., R.P. Sutmuller, A.A. Hurwitz, J. Ziskin, J. Villasenor, J.P. Medema, W.W. Overwijk, N.P. Restifo, C.J. Melief, R. Offringa, and J.P. Allison. 2001. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194:481-489.
49. Levitsky, H.I., A. Lazenby, R.J. Hayashi, and D.M. Pardoll. 1994. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 179:1215-1224.
50. Freeman, G.J., A.J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L.J. Fitz, N. Malenkovich, T. Okazaki, M.C. Byrne, H.F. Horton, L. Fouser, L. Carter, V. Ling, M.R. Bowman, B.M. Carreno, M. Collins, C.R. Wood, and T. Honjo. 2000. Engagement of the PD- 1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034.
51. Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5:1365-1369.
52. Kanai, T., T. Totsuka, K. Uraushihara, S. Makita, T. Nakamura, K. Koganei, T. Fukushima, H. Akiba, H. Yagita, K. Okumura, U. Machida, H. Iwai, M. Azuma, L. Chen, and M. Watanabe. 2003. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol 171:4156-4163.
53. Ghebeh, H., S. Mohammed, A. Al-Omair, A. Qattan, C. Lehe, G. Al-Qudaihi, N. Elkum, M. Alshabanah, S. Bin Amer, A. Tulbah, D. Ajarim, T. Al-Tweigeri, and S. Dermime. 2006. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8:190-198.
54. Dong, H., S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, V.A. Lennon, E. Celis, and L. Chen. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793-800.
55. Ohigashi, Y., M. Sho, Y. Yamada, Y. Tsurui, K. Hamada, N. Ikeda, T. Mizuno, R. Yoriki, H. Kashizuka, K. Yane, F. Tsushima, N. Otsuki, H. Yagita, M. Azuma, and Y. Nakajima. 2005. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand- 2 expression in human esophageal cancer. Clin Cancer Res 11:2947-2953.
56. Salih, H.R., S. Wintterle, M. Krusch, A. Kroner, Y.H. Huang, L. Chen, and H. Wiendl. 2006. The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol 34:888-894.
57. Konishi, J., K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura. 2004. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10:5094-5100.
58. Tsushima, F., K. Tanaka, N. Otsuki, P. Youngnak, H. Iwai, K. Omura, and M. Azuma. 2006. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol 42:268-274.
59. Thompson, R.H., M.D. Gillett, J.C. Cheville, C.M. Lohse, H. Dong, W.S. Webster, L. Chen, H. Zincke, M.L. Blute, B.C. Leibovich, and E.D. Kwon. 2005. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 104:2084-2091.
60. Thompson, R.H., M.D. Gillett, J.C. Cheville, C.M. Lohse, H. Dong, W.S. Webster, K.G. Krejci, J.R. Lobo, S. Sengupta, L. Chen, H. Zincke, M.L. Blute, S.E. Strome, B.C. Leibovich, and E.D. Kwon. 2004. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101:17174-17179.
61. Brown, J.A., D.M. Dorfman, F.R. Ma, E.L. Sullivan, O. Munoz, C.R. Wood, E.A. Greenfield, and G.J. Freeman. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170:1257-1266.
62. Mazanet, M.M., and C.C. Hughes. 2002. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169:3581-3588.
63. Dong, H., G. Zhu, K. Tamada, D.B. Flies, J.M. van Deursen, and L. Chen. 2004. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 20:327-336.
64. Iwai, Y., M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293-12297.
65. Blank, C., I. Brown, A.C. Peterson, M. Spiotto, Y. Iwai, T. Honjo, and T.F. Gajewski. 2004. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64:1140-1145.
66. Trinchieri, G., and P. Scott. 1999. Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 238:57-78.
67. Iwai, Y., S. Terawaki, and T. Honjo. 2005. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 17:133-144.
68. Strome, S.E., H. Dong, H. Tamura, S.G. Voss, D.B. Flies, K. Tamada, D. Salomao, J. Cheville, F. Hirano, W. Lin, J.L. Kasperbauer, K.V. Ballman, and L. Chen. 2003. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63:6501-6505.
69. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307.
70. Hirano, F., K. Kaneko, H. Tamura, H. Dong, S. Wang, M. Ichikawa, C. Rietz, D.B. Flies, J.S. Lau, G. Zhu, K. Tamada, and L. Chen. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65:1089-1096.
71. Melero, I., W.W. Shuford, S.A. Newby, A. Aruffo, J.A. Ledbetter, K.E. Hellstrom, R.S. Mittler, and L. Chen. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682-685.